Superiority of F-18 FDG PET imaging for detection of a pheochromocytoma

Clinical Nuclear Medicine

Volumn 31, Issue 1, 2006, Pages 13-15

  Sood, Ravi ^a,b   Story, Anna ^a   Rossleigh, Monica A ^a   Haindl, Walter ^a   Guille, Jennifer ^a   Pillai, Dilo ^a  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b NONE   (United States)

Author keywords

Coincidence PET; Extraadrenal pheochromocytoma; F 18 fluorodeoxyglucose (F 18 FDG); I 123 MIBG SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE TECHNETIUM TC 99M; FLUORODEOXYGLUCOSE F 18; IODINE 123; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HEART NEOPLASMS; HUMANS; IMAGE ENHANCEMENT; KIDNEY NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; PREGNANCY; RADIOPHARMACEUTICALS;

EID: 29444454162     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000191349.47208.2a     Document Type: Article

References (16)

1. Ilias I, Pacak K. Clinical problem solving; current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;89:479-492.
2. Jalil ND, Pattou FN, Combemale F, et al. Effectiveness and limits of preoperative imaging studies for the localization of pheochromocytomas and paraganglioma: a review of 282 Cases. Eur J Surg. 1998;154:223-228.
3. Glowniak JV, Kilty JE, Amara SG, et al. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993;34:1140-1146.
4. Jacques S, Tobes MC, Sisson JC, Baker JA. Mechanism of uptake of norepinephrine and metaiodobenzylguanidine into cultured human pheochromocytoma cells [Abstract]. J Nucl Med. 1984;25:122.
5. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmaceutical guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513-521.
6. Tobes MC, Jacques S, Lloyd RV, et al. Comparison of the in-vitro pharmacodynamics of metaiodobenzylguanidine (MIBG) to the in vivo scintigraphy [Abstract]. Nucl Med Commun. 1985;6:585.
7. Shulkin BL, Wieland DM, Schwaiger M, et al. PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med. 1992;33:1125-1131.
8. 18F-labelled deoxyglucose. Eur J Surg. 2001;167:866-870.
9. Proye C, Fossati P, Fontaine P, et al. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery. 1986;100:1154-1162.
10. Shulkin BL, Koeppe RA, Francis IR, et al. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG. Radiology. 1993;186:711-715.
11. Ilias I, Yu J, Carrasquillo J, et al. Superiority of 6-(18F)- fluorodopamine positron emission tomography versus I-131 MIBG scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083-4087.
12. 131I] iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med. 1983;24:1127-1134.
13. Manger WM. Heart imaging in the diagnosis of pheochromocytoma and assessment of catecholamines uptake [Teaching Editorial]. J Nucl Med. 1983;24:1194-1196.
14. Shulkin BL, Thompson N, Shapiro B, et al. Pheochromocytomas: imaging with 2-(Fluorine-18) fluro-2-deoxy-D-glucose PET. Radiology. 1999;212:35-41.
15. Landsberg L. Chromogranin A [Editorial]. N Engl J Med. 1984;311:794-795.
16. Bomanji J, Levison DA, Flatman WD, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987;28:973-978.